No Data
No Data
Compass Therapeutics Price Target Announced at $32.00/Share by D. Boral Capital
Compass Point Initiates Coverage On NCR Atleos With Buy Rating, Announces Price Target of $57
Compass Point Downgrades Innovative Ind Props to Neutral, Lowers Price Target to $78
Compass Health Celebrates Second Donation From Longtime Partner for Its State-of-the-Art Regional Center for Intensive Behavioral Health Needs
Compass Mining Scales Texas Operations With 25 MW Bitcoin Mining Facility, Plans Further Expansion
Institutional Investors in Compass Diversified (NYSE:CODI) Lost 4.3% Last Week but Have Reaped the Benefits of Longer-term Growth